Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”) and SEEDSUPPLY Inc. (CEO: Naoki Tarui / HQ: Kanagawa, hereinafter “SEEDSUPPLY”) hereby announce the start of joint research.
SEMEN SUPPLY (https://www.seedsupply.co.jp/) proposes an agile small molecule drug discovery process that uses binder selection technology as a proprietary method to screen compounds. This technology can screen compounds for any protein or RNA, thereby providing drug discovery seeds for various drug discovery goals, including those for which measurement of biochemical activity is challenging. In addition, a database of binding compounds created for specific drug discovery target classes is used for target selection to improve the efficiency and success rate of drug discovery processes. In addition, the database offers the potential for wider application.
elixir (https://www.elix-inc.com/) is an AI drug discovery company with the mission “Rethinking Drug Discovery”. To reduce costs and time while increasing the success rate of the drug discovery pipeline, Elix focuses on the use of machine learning in projects targeting pharmaceutical companies, universities and research institutes. Elix has developed and released Elix Discovery™, the all-in-one platform for AI drug discovery that provides everything from property prediction models and molecular design to consulting and implementation support in one package (https://www.elix-inc.com/news/newsrelease/1620/). In addition to the current provision of drug discovery support, Elix is also considering future in-house drug discovery activities.
In this joint research project, SEEDSUPPLY will use Elix’s proprietary AI technology with the aim of drastically increasing the efficiency of screening processes. Elix will integrate SEEDSUPPLY’s wealth of data, particularly its data on important drug discovery targets such as membrane proteins, into the AI’s training pipeline, thereby advancing the technology for in silico Techniques…
